|
|
|
 |
| Location: Home -
Products - Active Pharma Ingredients(API) - Anti-Cancer(Oncology) API
|
Roscovitine(Seliciclib)
| Catalogue No. : |
C14123 |
| Product Name: |
Roscovitine(Seliciclib) |
| Synonym: |
CYC202;R-roscovitine;6-(Benzylamino)-2(R)-[[1-(hydroxymethyl)propyl]amino]-9-isopropylpurine |
| Chemical Name: |
2-(R)-[[9-(1-Methylethyl)-6-[(phenylmethyl)amino]-9H-purin-2-yl]amino]-1-butanol |
| CAS No. : |
186692-46-6 |
| Structure : |
|
| Molecular Formula: |
C19H26N6O |
| Molecular Weight: |
354.45 |
| Appearance: |
White solid |
| Solubility: |
Soluble in DMSO and CHCl3 |
| Purity: |
>99% |
| Usage: |
Cyclin-dependent kinases (CDKs) are key regulators of cell cycle progression and are therefore promising targets for cancer therapy. (R)-Roscovitine is a potent inhibitor of CDK2/cyclin E with an IC50 value of 0.1 µM.It also inhibits CDK7/cyclin H, CDK5/p35, and cell division cycle (cdc)/cyclin B with IC50 values of 0.49, 0.16, and 0.65 µM, respectively. |
|
| Products protected by valid patents are not offered for sale in countries, where the sale of such products constitutes a patent infringement. As it is impossible for us to be informed about the patent situation in all countries, the liability for patent infringement is exclusively to be understood as buyer's risk. |
|
|
